Company patents
Promega Corporation
Promega Corporation's patent strategy reveals a surprising diversification beyond its core Material & Chemical Analysis (52.2% of portfolio) and Heterocyclic Compounds (Pharma) (40.0% of portfolio) areas, with a notable emerging focus on Peptides & Proteins, which saw a significant 66.7% year-over-year growth in 2026 so far, despite a general decline in patenting across many other categories in 2026.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
90 US filings (since 2023) · 12 categories · 10 themes
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Methods and reagents designed to improve the specificity, efficiency, or yield of nucleic acid capture, ligation, amplification, or library preparation steps, particularly for sequencing applications or quantitative analysis.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Methods and kits for amplifying nucleic acids at a constant temperature, enabling faster results and point-of-care applications, often used for pathogen or contamination detection.
Development and optimization of organic chemical compounds and their structures, including guest-host systems and metal complexes, used within the emission layer to achieve specific light emission characteristics such as color, efficiency, and operational lifetime.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Assays leveraging CRISPR-Cas systems (e.g., Cas12, Cas13) for highly specific and sensitive detection of target nucleic acids, often involving collateral cleavage activity or reporter molecules.
Self-contained or modular devices designed to automate and integrate multiple steps of molecular diagnostic assays, from sample preparation to result interpretation, often for point-of-care or high-throughput applications.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Patents
Showing 1-10 of 147